Keros Therapeutics, Inc. (KROS) Balance Sheet

The downward trajectory in total assets suggests that the company is currently in a phase of capital depletion as it advances its pipeline. Investors should monitor whether the current asset base remains sufficient to reach critical clinical milestones without necessitating further dilutive equity raises.

This high current ratio is largely a function of the company's cash-heavy balance sheet relative to its current liabilities. While this provides a comfortable cushion, the rapid decline in cash from $720.5M in 2025Q1 to $281.5M in 2026Q1 suggests that the burn rate remains the primary determinant of future financing needs.

The minimal debt load indicates that the company's capital structure is almost entirely equity-funded, which is typical for early-stage biotech firms. This lack of leverage provides management with significant flexibility to pursue non-dilutive financing options should clinical data warrant a shift in capital allocation strategy.

The persistent growth of the accumulated deficit highlights the high-risk nature of the company's R&D-heavy business model. Investors should interpret this as a reflection of the long-term investment required to bring specialized biologics to market, rather than an indicator of operational inefficiency.